That is the distinction I keep failing to hold on to. Written down now.
Publishing an inconvenient result: a case study posts 61–71
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Picking up post #60: that is the part I would want checked first.
Repeat determination on the same product line months apart is the measurement that speaks to consistency, and consistency is what most buyers actually want.
Caveat: everything above assumes the paperwork is what it says it is.
Collapsed as off-topic by two members at trust level 3 or above
The reason publishing an inconvenient result keeps being re-asked is that the answer is conditional and people quote it without the condition. It is not that the answer is unknown.
Where two services agree with each other and with the declared figure, that is a genuinely strong result and it applies to that lot.
I had written a reply contradicting post #62 and deleted it. Here is what survived.
Reading back through the publishing an inconvenient result threads from last year, the same three questions come up every time and only one of them has ever been answered properly. That seems like a documentation gap rather than a knowledge gap.
Nobody has said the unglamorous part of publishing an inconvenient result yet, so: most of the variation is explained by things that are boring to write about and easy to check.
Collapsed as off-topic by two members at trust level 3 or above
Post #68 is the version of this I will quote in future. One addition.
On publishing an inconvenient result: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here including this one.
Where I part company with post #66, and it is a narrow parting.
Interpreting a result: a purity figure is one measurement on one vial on one day. Agreement across two services is much stronger. A single high number does not establish a pattern.
The part I am sure of is shorter than the part I have written.
This topic was referenced in
- Submitting a sample: the process end to endSourcing › Independent verification · 114 replies
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
What a documentation review can and cannot tell you — a second dataset
The question in the title: What a documentation review can and cannot tell you — a second dataset I will give what I have already checked below so nobody repeats it. Posting a small dataset on documentation…
|
4 | 170 | 4mo | |
|
Choosing which test to pay for, given a fixed budget
On the subject in the title: Choosing which test to pay for, given a fixed budget Working notes rather than a conclusion. A question about how a record should be read rather than about a supplier. We have…
|
+60 | 70 | 49k | 3mo |
|
Aggregate verification data across the directory, with caveats
On the subject in the title: Aggregate verification data across the directory, with caveats Working notes rather than a conclusion. I have spent a fortnight trying to pin aggregate verification data down and…
|
+64 | 74 | 4.6k | 14h |
|
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ — a second dataset
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ — a second dataset I have a specific reason for asking rather than idle curiosity, and the context is below. Posting a small dataset on…
|
+42 | 46 | 46k | 2mo |
|
[2026 update] What a purity-only report leaves out
The question in the title: What a purity-only report leaves out I will give what I have already checked below so nobody repeats it. Structured report rather than an opinion, following the format the…
|
+97 | 103 | 5.2k | 3mo |
Related topics — sharing the tags Medutest, VendorInvestigate, third-party testing
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
What a purity-only report leaves out
What a purity-only report leaves out — that is the question, and I have not found it answered plainly anywhere I have looked. Purity-only: setting out the arithmetic in full, because I have had to do it twice…
|
+92 | 105 | 4k | 8mo |
|
Documenting a supplier's response to a discrepancy
On the subject in the title: Documenting a supplier's response to a discrepancy Working notes rather than a conclusion. A question about how a record should be read rather than about a supplier. We have…
|
+44 | 49 | 589 | 8h |
|
Coming back to: What consumer-accessible tests can and cannot determine
Asking directly, because I could not find a straight answer: What consumer-accessible tests can and cannot determine Something about consumer-accessible tests does not reconcile and I would like a second pair…
|
+4 | 8 | 25k | 22mo |
|
A comparison of home results against a laboratory result on the same vial
Posting this under the heading it deserves: A comparison of home results against a laboratory result on the same vial Everything below is what sits behind that. Comparison of home results against: setting out…
|
+61 | 65 | 35k | 8mo |
|
A comparison of home results against a laboratory result on the same vial — does this still hold?
A comparison of home results against a laboratory result on the same vial — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Comparison of home…
|
+2 | 6 | 15k | 11h |